找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Radiotherapy in Prostate Cancer; Innovative Technique Hans Geinitz,Mack Roach III,Nicholas van As Book 2015 Springer-Verlag Berlin Heidelbe

[復(fù)制鏈接]
樓主: Addiction
21#
發(fā)表于 2025-3-25 06:30:44 | 只看該作者
22#
發(fā)表于 2025-3-25 10:14:41 | 只看該作者
Prophylactic Treatment of the Pelvic Lymphatics: Contra,ymph nodes irradiation. Several biases including technical radiotherapy features (target volume, dose) are discussed. Radiation oncologists should be encouraged to participate in the ongoing RTOG 094 international randomized study.
23#
發(fā)表于 2025-3-25 14:21:10 | 只看該作者
Book 2015need to be put together to provide the prostate cancer patient with high-level optimized radiation treatment. This book examines in detail the role of these innovative radiation techniques in the management of prostate cancer. In addition, a variety of current controversies regarding treatment are c
24#
發(fā)表于 2025-3-25 16:18:41 | 只看該作者
25#
發(fā)表于 2025-3-25 22:04:06 | 只看該作者
Hypo-fractionation in Prostate Cancer: Biological Aspects,cer is lower than that for rectal complications. This chapter will—after general considerations on fractionation and the α/? ratio—summarize the current scientific status on the assumed α/? for prostate cancer and relevant normal tissue complications and discuss the potential and the caveats of hypo-fractionation for prostate cancer.
26#
發(fā)表于 2025-3-26 03:31:52 | 只看該作者
27#
發(fā)表于 2025-3-26 05:20:48 | 只看該作者
Dose Escalation: An Update on Randomised Clinical Trials,elationship to other endpoints such as overall survival and disease-specific survival is still unclear, with different dose-correlations detected in different studies. Currently, several phase III randomised trials published in the recent years provided their long-term results with high level of evidence.
28#
發(fā)表于 2025-3-26 08:33:52 | 只看該作者
29#
發(fā)表于 2025-3-26 13:33:10 | 只看該作者
Treatment of Clinically Involved Lymph Nodes,lvic nodal disease without further metastatic spread is highly individual as no clear evidence on the superiority of any approach exists. Practical aproaches can be extrapolated from studies on high-risk patients.
30#
發(fā)表于 2025-3-26 17:27:28 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-17 02:04
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
滨海县| 当雄县| 博野县| 合水县| 年辖:市辖区| 焦作市| 沙河市| 顺昌县| 长乐市| 宜章县| 奉节县| 堆龙德庆县| 夏河县| 延川县| 宽甸| 德格县| 崇左市| 宝丰县| 峡江县| 额敏县| 新野县| 呼图壁县| 肇源县| 澎湖县| 丰原市| 平和县| 藁城市| 太康县| 石泉县| 闽侯县| 桃江县| 兰西县| 呼伦贝尔市| 奉贤区| 兰州市| 治多县| 昌都县| 威远县| 红原县| 青龙| 隆安县|